These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 8427668

  • 1. Commentary on Shigetomi and Kuchel's work on DOPA decarboxylation.
    Zimlichman R.
    Am J Hypertens; 1993 Jan; 6(1):89-90. PubMed ID: 8427668
    [No Abstract] [Full Text] [Related]

  • 2. Defective 3,4-dihydroxyphenylalanine decarboxylation to dopamine in hydralazine-treated hypertensive patients may be pyridoxine remediable.
    Shigetomi S, Kuchel O.
    Am J Hypertens; 1993 Jan; 6(1):33-40. PubMed ID: 8427659
    [Abstract] [Full Text] [Related]

  • 3. Decarboxylation of 3,4-dihydroxyphenylalanine (DOPA) by erythrocytes: a reaction promoted by methemoglobin and other ferriheme proteins.
    Tate SS, Orlando J, Meister A.
    Proc Natl Acad Sci U S A; 1972 Sep; 69(9):2505-8. PubMed ID: 4403564
    [Abstract] [Full Text] [Related]

  • 4. Influence of guanethidine on the cerebrospinal fluid and blood catecholamines in essential hypertension.
    Ciplea A, Bubuianu G, Drăgulescu N.
    Rev Roum Physiol; 1973 Sep; 10(4):270-3. PubMed ID: 4723334
    [No Abstract] [Full Text] [Related]

  • 5. [Effect of atenolol on the excretion of catecholamines and their metabolites and dihydroxyphenylalanine (DOPA) in patients with essential hypertension].
    Wocial B, Januszewicz W, Sznajderman M, Feltynowski T.
    Pol Arch Med Wewn; 1982 Mar; 67(3):87-91. PubMed ID: 6810328
    [No Abstract] [Full Text] [Related]

  • 6. [Decarboxylation of DOPA by the myocardium of guinea pigs].
    MUELLER PB, LANGEMANN H.
    Klin Wochenschr; 1962 Sep 01; 40():911-3. PubMed ID: 14476936
    [No Abstract] [Full Text] [Related]

  • 7. [Coenzyme role of hydrazones of pyridoxal phosphate with respect to dopa decarboxylation].
    GONNARD P, NGUYEN CHI JP.
    Bull Soc Chim Biol (Paris); 1959 Sep 01; 41():1455-61. PubMed ID: 13850964
    [No Abstract] [Full Text] [Related]

  • 8. The action of antidecarboxylases on the conversion of 3,4-dihydroxyphenylalanine to dopamine in vivo.
    MURPHY GF, SOURKES TL.
    Arch Biochem Biophys; 1961 May 01; 93():338-43. PubMed ID: 13726974
    [No Abstract] [Full Text] [Related]

  • 9. [Some functional consequences of the blood-brain barrier for catecholamines and their precursors].
    Tissot R, Gaillard JM, Constantinidis J, Geissbühler P.
    Acta Physiol Pol; 1973 May 01; 24(1):61-70. PubMed ID: 4716349
    [No Abstract] [Full Text] [Related]

  • 10. Dopa uptake and catecholamine content in heart and spleen.
    WEGMANN A, KAKO K, CHRYSOHOU A.
    Am J Physiol; 1961 Oct 01; 201():673-6. PubMed ID: 14005571
    [No Abstract] [Full Text] [Related]

  • 11. Extraneuronal binding of catecholamines and 3,4-dihydroxyphenylalanine (dopa) in salivary glands.
    Hamberger B, Norberg KA, Olson L.
    Acta Physiol Scand; 1967 Oct 01; 69(1):1-12. PubMed ID: 5340156
    [No Abstract] [Full Text] [Related]

  • 12. Effect of protein ingestion on urinary dopamine excretion. Evidence for the functional importance of renal decarboxylation of circulating 3,4-dihydroxyphenylalanine in man.
    Williams M, Young JB, Rosa RM, Gunn S, Epstein FH, Landsberg L.
    J Clin Invest; 1986 Dec 01; 78(6):1687-93. PubMed ID: 3097077
    [Abstract] [Full Text] [Related]

  • 13. Origins and significance of dopa and catecholamine metabolites in body fluids.
    Kopin IJ.
    Pharmacopsychiatry; 1992 Jan 01; 25(1):33-6. PubMed ID: 1579604
    [No Abstract] [Full Text] [Related]

  • 14. Nuclear DNA ploidy pattern and tissue levels of dihydroxyphenylalanine and catecholamines in pheochromocytoma.
    Sasagawa I, Nakada T, Kubota Y, Ishigooka M, Sawamura T, Suzuki Y.
    Urol Int; 1995 Jan 01; 54(4):181-3. PubMed ID: 7610501
    [Abstract] [Full Text] [Related]

  • 15. Decarboxylation of radioactive DOPA by erythrocytes in schizophrenia.
    Tran N, Laplante M, Lebel E.
    Br J Psychiatry; 1971 Apr 01; 118(545):465-6. PubMed ID: 5576648
    [No Abstract] [Full Text] [Related]

  • 16. [Study of catecholamines and DOPA in obsidan treatment of patients with circulatory insufficiency].
    Kiseleva ZM, Orlova AI.
    Ter Arkh; 1979 Apr 01; 51(1):49-53. PubMed ID: 432830
    [No Abstract] [Full Text] [Related]

  • 17. A role for glutathione as an endogenous inhibitor of the nonenzymatic decarboxylation of DOPA.
    Mackowiak ED, Hare TA, Vogel WH.
    Biochem Med; 1975 Feb 01; 12(2):137-42. PubMed ID: 1137574
    [No Abstract] [Full Text] [Related]

  • 18. Inhibition of dopa decarboxylation by RO4-4602, MK 485 and MK 486 in human liver homogenates.
    Vogel WH, Mahoney K, Hare TA.
    Arch Int Pharmacodyn Ther; 1972 Feb 01; 198(1):85-93. PubMed ID: 4538242
    [No Abstract] [Full Text] [Related]

  • 19. Capacity for amine-precursor uptake and decarboxylation of argyrophil cell adenocarcinoma of the endometrium.
    Inoue M, Ueda G, Yamasaki M, Tanaka Y, Hiramatsu K, Sakumoto T, Kurachi K, Maeyama K, Yamatodani A.
    Gynecol Oncol; 1982 Feb 01; 13(1):19-25. PubMed ID: 6120883
    [No Abstract] [Full Text] [Related]

  • 20. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
    Cumming P, Gjedde A.
    Synapse; 1998 May 01; 29(1):37-61. PubMed ID: 9552174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.